Your browser is no longer supported. Please, upgrade your browser.
Settings
ARWR Arrowhead Pharmaceuticals, Inc. daily Stock Chart
ARWR [NASD]
Arrowhead Pharmaceuticals, Inc.
Index- P/E72.17 EPS (ttm)0.46 Insider Own2.80% Shs Outstand93.69M Perf Week3.61%
Market Cap3.09B Forward P/E- EPS next Y-0.31 Insider Trans-14.61% Shs Float93.31M Perf Month10.12%
Income45.50M PEG9.85 EPS next Q0.15 Inst Own73.40% Short Float17.16% Perf Quarter17.12%
Sales136.80M P/S22.59 EPS this Y-39.90% Inst Trans0.68% Short Ratio12.37 Perf Half Y76.84%
Book/sh2.38 P/B13.86 EPS next Y-141.30% ROA16.20% Target Price37.71 Perf Year156.06%
Cash/sh2.53 P/C13.04 EPS next 5Y7.33% ROE26.20% 52W Range10.41 - 36.80 Perf YTD165.54%
Dividend- P/FCF20.38 EPS past 5Y12.90% ROI-57.00% 52W High-10.38% Beta1.57
Dividend %- Quick Ratio2.80 Sales past 5Y123.40% Gross Margin- 52W Low216.81% ATR1.52
Employees116 Current Ratio2.80 Sales Q/Q5770.00% Oper. Margin29.60% RSI (14)65.76 Volatility3.73% 4.98%
OptionableYes Debt/Eq0.00 EPS Q/Q215.50% Profit Margin33.30% Rel Volume0.66 Prev Close32.55
ShortableYes LT Debt/Eq0.00 EarningsNov 04 AMC Payout0.00% Avg Volume1.29M Price32.98
Recom1.80 SMA2011.70% SMA508.20% SMA20043.52% Volume851,402 Change1.32%
Oct-03-19Initiated Robert W. Baird Outperform $39
Sep-07-18Upgrade B. Riley FBR Neutral → Buy $18 → $19
Sep-06-18Reiterated Chardan Capital Markets Buy $17.50 → $24.50
Aug-08-18Reiterated Cantor Fitzgerald Overweight $13 → $18
Jul-02-18Reiterated Chardan Capital Markets Buy $9.50 → $16
May-09-18Upgrade Cantor Fitzgerald Neutral → Overweight $13
Mar-27-18Initiated Jefferies Buy $10
Feb-12-18Reiterated Cantor Fitzgerald Neutral $2 → $5
Feb-12-18Reiterated B. Riley FBR, Inc. Neutral $3 → $4
Jan-05-18Initiated B. Riley FBR, Inc. Neutral $3
Nov-27-17Upgrade Piper Jaffray Neutral → Overweight
Sep-18-17Upgrade William Blair Mkt Perform → Outperform
Nov-30-16Downgrade William Blair Outperform → Mkt Perform
Nov-30-16Downgrade Piper Jaffray Overweight → Neutral
Nov-30-16Downgrade Chardan Capital Markets Buy → Neutral $8 → $2
Nov-30-16Downgrade Cantor Fitzgerald Buy → Hold
Nov-10-16Reiterated Chardan Capital Markets Buy $10 → $8
Aug-18-16Initiated Cantor Fitzgerald Buy $15
May-19-16Initiated Chardan Capital Markets Buy $12
Sep-25-15Reiterated Piper Jaffray Overweight $12 → $20
Oct-04-19 12:11PM  Medical stocks on the move: AbbVie, Arrowhead Pharmaceuticals and Zynex MarketWatch
Oct-02-19 04:15PM  Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics Business Wire
Sep-30-19 04:00PM  Arrowhead Pharmaceuticals to Participate in Upcoming October 2019 Conferences Business Wire
Sep-27-19 09:15AM  ARWR: Broad-Based Pipeline Progress. Three Pivotal Studies, Value-Inflection Opportunities In View. Zacks Small Cap Research
Sep-20-19 04:00PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
10:19AM  Is Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Paid Enough Relative To Peers? Simply Wall St.
Sep-16-19 03:00AM  Arrowhead Pharmaceuticals Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3 Business Wire
Sep-09-19 06:51AM  Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar? Zacks -8.92%
Sep-08-19 07:28PM  Here's Why Arrowhead Pharmaceuticals Rose 17.6% in August Motley Fool
Aug-30-19 04:00PM  Arrowhead Pharmaceuticals to Participate in Upcoming September 2019 Conferences Business Wire
Aug-29-19 04:21PM  Why This Newly Profitable Biotech Stock Is Flirting With A Breakout Investor's Business Daily
11:02AM  Arrowhead Pharmaceuticals and three other stocks to watch MarketWatch
Aug-28-19 03:16PM  Is Arrowhead Pharmaceuticals Inc (ARWR)s Recently Published U.S. Patent Application A Blockbuster? Insider Monkey
07:30AM  Arrowhead Collaborator Janssen Begins REEF-1 Phase 2b Combination Study in Patients with Chronic Hepatitis B Infection Business Wire
Aug-21-19 12:37PM  Arrowhead Pharmaceuticals: Buy at the High? Motley Fool
Aug-19-19 11:44AM  Arrowhead Pharma Shares Quietly See Big Buy Demand Investopedia +8.11%
Aug-15-19 11:59AM  Could The Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ownership Structure Tell Us Something Useful? Simply Wall St.
09:00AM  BioBoyScouts Online Biotech Valuation Calculators Help Small Investors See Value in Arrowhead Pharmaceuticals (ARWR) Insider Monkey
Aug-12-19 06:10AM  Edited Transcript of ARWR earnings conference call or presentation 5-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-19 07:30AM  Arrowhead Pharmaceuticals Doses First Patient in SEQUOIA Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease Business Wire
Aug-06-19 10:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
06:00AM  What You'll Want to Know About Arrowhead Pharmaceuticals' Q3 Update Motley Fool
Aug-05-19 11:23PM  Arrowhead Research Corp (ARWR) Q3 2019 Earnings Call Transcript Motley Fool -6.46%
04:00PM  Arrowhead Pharmaceuticals Reports Fiscal 2019 Third Quarter Results Business Wire
Jul-24-19 07:30AM  Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Third Quarter Results Business Wire
Jul-16-19 04:00PM  Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-ANG3 Business Wire
Jul-10-19 07:27AM  How Does Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Affect Your Portfolio Volatility? Simply Wall St.
Jul-08-19 07:30AM  Arrowhead Pharmaceuticals to Participate in Roth RNA Revolution Conference Business Wire
Jun-28-19 04:31PM  Highly Rated Biotech Downgraded After Breaking Out And Running 39% Investor's Business Daily -8.05%
07:32AM  The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO Benzinga
06:45AM  Arrowhead Pharma Heads Down Midday After Downgrade Investing.com
Jun-27-19 07:30AM  Arrowhead Pharmaceuticals Receives Fast Track Designation for ARO-AAT for Treatment of Alpha-1 Liver Disease Business Wire
Jun-24-19 01:38PM  Hedge Funds Have Never Been This Bullish On Arrowhead Pharmaceuticals, Inc. (ARWR) Insider Monkey
Jun-21-19 06:45PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
07:30AM  Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-APOC3 Business Wire
Jun-14-19 02:59PM  7 Top-Rated Biotech Stocks to Invest In Today InvestorPlace
Jun-12-19 03:32PM  Edited Transcript of ARWR earnings conference call or presentation 12-Dec-17 9:30pm GMT Thomson Reuters StreetEvents
Jun-11-19 03:44PM  Edited Transcript of ARWR earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
Jun-10-19 10:02AM  Read This Before Judging Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) ROE Simply Wall St.
06:30AM  Here's Why Arrowhead Pharmaceuticals Surged 31.9% in May Motley Fool
May-31-19 04:00PM  Arrowhead Pharmaceuticals to Present at Upcoming June 2019 Conferences Business Wire
May-21-19 04:27PM  Here's Why Arrowhead Pharmaceuticals Skyrocketed 12.7% Today Motley Fool +12.72%
07:40AM  The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails Benzinga
May-20-19 05:56PM  Kontoor Brands and Arrowhead Pharmaceuticals Set to Join S&P SmallCap 600 PR Newswire
03:45PM  ARWR: ARO-AAT Ph 2/3 Detailed, Could Serve as FDA Pivotal Study. Continued Broad-Based Pipeline Progress Zacks Small Cap Research
May-09-19 01:23AM  Arrowhead Research Corp (ARWR) Q2 2019 Earnings Call Transcript Motley Fool +6.11%
May-08-19 04:06PM  Arrowhead Research: Fiscal 2Q Earnings Snapshot Associated Press
04:00PM  Arrowhead Pharmaceuticals Reports Fiscal 2019 Second Quarter Results Business Wire
02:30PM  Arrowhead Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
May-02-19 04:05PM  Heres What Hedge Funds Think About Arrowhead Pharmaceuticals, Inc. (ARWR) Insider Monkey
07:30AM  Arrowhead Pharmaceuticals to Present at Upcoming May 2019 Conferences Business Wire
May-01-19 07:06PM  Cramer's lighting round: The quarter won't be good, but buy this stock CNBC
Apr-25-19 03:01PM  Did You Miss Arrowhead Pharmaceuticals's (NASDAQ:ARWR) Impressive 217% Share Price Gain? Simply Wall St.
Apr-24-19 04:00PM  Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Second Quarter Results Business Wire
07:30AM  Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from Janssen Business Wire
Apr-21-19 07:57AM  Revamp at Silence does little to improve investors wellbeing Financial Times
Apr-15-19 07:30AM  Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease Business Wire
Apr-12-19 12:45PM  Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress Business Wire
06:00AM  Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents and Reverses Alpha-1 Liver Disease at The International Liver Congress Business Wire
Apr-11-19 09:27AM  4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics Zacks
Mar-29-19 04:30PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
Mar-27-19 07:35AM  Research Report Identifies Criteo S.A, Ferrari N.V, Freshpet, ServiceMaster Global, CSG Systems International, and Arrowhead Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-22-19 04:16PM  Produce with the most pesticides in your grocery store Yahoo Finance -6.82%
Mar-18-19 07:30AM  Arrowhead Pharmaceuticals Files IND for Pivotal Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease Business Wire
Mar-11-19 07:30AM  Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia Business Wire
02:25AM  Here's Why Arrowhead Pharmaceuticals Gained 38.2% in February Motley Fool
Mar-07-19 08:01AM  Does Arrowhead Pharmaceuticals, Inc.s (NASDAQ:ARWR) CEO Salary Reflect Performance? Simply Wall St.
Mar-01-19 07:30AM  Arrowhead Pharmaceuticals to Present at Upcoming March 2019 Conferences Business Wire
Feb-12-19 12:00PM  ARWRs 2019 Goals Include Data From Several Studies, Initiation of Ph2 ARO-AAT Zacks Small Cap Research
11:14AM  Edited Transcript of ARWR earnings conference call or presentation 7-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
08:30AM  Biotech Stocks Rising ACCESSWIRE
Feb-08-19 12:20PM  Here's Why Arrowhead Pharmaceuticals Gained as Much as 15.8% Today Motley Fool +17.74%
Feb-07-19 11:24PM  Arrowhead Pharmaceuticals Inc (ARWR) Q1 2019 Earnings Conference Call Transcript Motley Fool
05:25PM  Arrowhead Research: Fiscal 1Q Earnings Snapshot Associated Press
04:00PM  Arrowhead Pharmaceuticals Reports Fiscal 2019 First Quarter Results Business Wire
08:08AM  The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut Benzinga
Jan-31-19 07:35AM  Report: Exploring Fundamental Drivers Behind TD Ameritrade Holding, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Nucor, Portland General Electric, and TrueBlue New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jan-30-19 07:00AM  Have Insiders Been Selling Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares? Simply Wall St.
Jan-24-19 04:00PM  Arrowhead Pharmaceuticals to Webcast Fiscal 2019 First Quarter Results Business Wire
Jan-22-19 02:48PM  5 Hot Small-Cap Stocks That Are a Bit Too Toasty InvestorPlace -9.78%
Jan-12-19 09:07AM  Here's Why Arrowhead Pharmaceuticals Shot 237.5% Higher in 2018 Motley Fool
Jan-07-19 07:30AM  Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia Business Wire +7.06%
07:30AM  Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases Business Wire
Jan-06-19 09:16PM  Edited Transcript of ARWR earnings conference call or presentation 11-Dec-18 9:30pm GMT Thomson Reuters StreetEvents
Dec-21-18 11:19PM  Arrowhead Research Corp (ARWR): Hedge Funds Are Snapping Up Insider Monkey -12.90%
Dec-17-18 06:06PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
Dec-12-18 04:51PM  Why Arrowhead Pharmaceuticals Surged 11% Higher Today Motley Fool +11.53%
08:07AM  The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel Benzinga
07:00AM  Today's Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Agios Pharmaceuticals ACCESSWIRE
12:13AM  Arrowhead Pharmaceuticals (ARWR) Q4 2018 Earnings Conference Call Transcript Motley Fool
Dec-11-18 04:00PM  Arrowhead Pharmaceuticals Reports Fiscal 2018 Year End Results Business Wire
08:22AM  The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings Benzinga
Dec-10-18 06:18PM  Here's Why Arrowhead Pharmaceuticals Jumped 14.1% in November Motley Fool
Dec-04-18 04:58PM  J&J Strikes Deal with argenx to Co-Develop Cancer Antibody Zacks -10.34%
Nov-30-18 07:25AM  Detailed Research: Economic Perspectives on Arrowhead Pharmaceuticals, NexGen Energy, ArcBest, Cigna, The Allstate, and Comtech Telecommunications What Drives Growth in Today's Competitive Landscape GlobeNewswire
Nov-27-18 07:30AM  Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results Business Wire
Nov-09-18 12:00PM  Arrowhead Pharmaceuticals Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting® 2018 Business Wire -5.60%
12:00PM  Arrowhead Pharmaceuticals Presents Late-Breaking Clinical Data on ARO-AAT at Liver Meeting® 2018 Business Wire
Nov-07-18 11:23AM  Here's Why Arrowhead Pharmaceuticals Dropped 33.6% in October Motley Fool +8.25%
Nov-01-18 07:30AM  Arrowhead Pharmaceuticals to Present at Upcoming November 2018 Conferences Business Wire +11.79%
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of ARO-HBV, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.; and Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anzalone Christopher RichardChief Executive OfficerOct 10Option Exercise5.2056,325292,8902,178,228Oct 11 07:31 PM
Anzalone Christopher RichardChief Executive OfficerOct 10Sale31.8356,3251,792,8252,121,903Oct 11 07:31 PM
Anzalone Christopher RichardChief Executive OfficerSep 25Sale28.2520,000565,0002,121,903Sep 27 09:16 PM
Anzalone Christopher RichardChief Executive OfficerSep 24Option Exercise5.1066,645339,8902,208,548Sep 24 09:12 PM
Anzalone Christopher RichardChief Executive OfficerSep 24Sale28.2066,6451,879,2402,141,903Sep 24 09:12 PM
Anzalone Christopher RichardChief Executive OfficerSep 23Option Exercise5.1041,755212,9512,183,658Sep 24 09:12 PM
Anzalone Christopher RichardChief Executive OfficerSep 23Sale29.0441,7551,212,5652,141,903Sep 24 09:12 PM
Anzalone Christopher RichardChief Executive OfficerSep 20Option Exercise5.104,25021,6752,146,153Sep 24 09:12 PM
Anzalone Christopher RichardChief Executive OfficerSep 20Sale29.004,250123,2502,141,903Sep 24 09:12 PM
PERRY MICHAEL SDirectorSep 11Sale30.0085,0002,550,00036,000Sep 11 08:09 PM
PERRY MICHAEL SDirectorSep 09Sale28.90100,0002,890,000121,000Sep 11 08:09 PM
Ferrari MauroDirectorJun 26Sale27.6117,756490,2431,900Jun 28 07:19 PM
Myszkowski Kenneth AllenChief Financial OfficerMay 31Option Exercise4.9435,000172,800313,536Jun 03 06:12 PM
O'Brien PatrickGeneral CounselMay 28Sale24.8830,000746,400203,000May 29 07:01 PM
Anzalone Christopher RichardChief Executive OfficerMay 24Option Exercise2.1349,448105,1102,141,903May 29 06:57 PM
Myszkowski Kenneth AllenChief Financial OfficerMay 21Sale22.0027,071595,562278,536May 22 05:44 PM
Anzalone Christopher RichardChief Executive OfficerApr 03Sale19.3050,000965,0002,092,455Apr 05 06:57 PM
GIVEN BRUCE DChief Operating OfficerMar 01Option Exercise2.0142,50085,425687,106Mar 01 08:42 PM
GIVEN BRUCE DChief Operating OfficerMar 01Sale19.9942,500849,575644,606Mar 01 08:42 PM
GIVEN DOUGLAS BDirectorFeb 26Option Exercise3.9265,000254,570240,130Feb 26 07:32 PM
GIVEN DOUGLAS BDirectorFeb 26Sale19.2565,0001,251,250175,130Feb 26 07:32 PM
GIVEN BRUCE DChief Operating OfficerFeb 25Option Exercise2.0142,50085,425687,106Feb 27 07:08 PM
GIVEN BRUCE DChief Operating OfficerFeb 25Sale18.9842,500806,650644,606Feb 27 07:08 PM
GIVEN DOUGLAS BDirectorFeb 22Sale18.053,00054,150175,130Feb 26 07:32 PM
GIVEN BRUCE DChief Operating OfficerFeb 19Option Exercise2.0142,50085,425687,106Feb 20 08:09 PM
Myszkowski Kenneth AllenChief Financial OfficerFeb 19Option Exercise5.208,00041,600313,607Feb 20 08:12 PM
Myszkowski Kenneth AllenChief Financial OfficerFeb 19Sale18.008,000144,000305,607Feb 20 08:12 PM
GIVEN BRUCE DChief Operating OfficerFeb 19Sale17.9842,500764,150644,606Feb 20 08:09 PM
GIVEN BRUCE DChief Operating OfficerFeb 15Sale17.6726,250463,838644,606Feb 20 08:09 PM
GIVEN BRUCE DChief Operating OfficerFeb 12Option Exercise2.0142,50085,425713,356Feb 12 08:58 PM
GIVEN BRUCE DChief Operating OfficerFeb 12Sale17.0642,500725,050670,856Feb 12 08:58 PM
GIVEN BRUCE DChief Operating OfficerFeb 11Option Exercise2.6211,66730,568825,023Feb 12 08:58 PM
GIVEN BRUCE DChief Operating OfficerFeb 11Sale15.96154,1672,460,995670,856Feb 12 08:58 PM
GIVEN BRUCE DChief Operating OfficerFeb 08Option Exercise2.6211,66730,568859,523Feb 12 08:58 PM
GIVEN BRUCE DChief Operating OfficerFeb 08Sale15.3446,167708,202813,356Feb 12 08:58 PM
GIVEN BRUCE DChief Operating OfficerFeb 05Sale14.4822,500325,800847,856Feb 07 08:35 PM
GIVEN BRUCE DChief Operating OfficerFeb 01Sale13.8528,500394,725870,356Feb 01 07:51 PM
GIVEN BRUCE DChief Operating OfficerJan 23Sale13.1517,500230,125898,856Jan 24 08:53 PM
GIVEN BRUCE DChief Operating OfficerJan 22Sale13.59152,0002,065,680916,356Jan 24 08:53 PM
GIVEN DOUGLAS BDirectorJan 22Sale13.583,00040,740178,130Jan 24 08:46 PM
O'Brien PatrickGeneral CounselJan 18Sale14.4372,0001,038,960233,000Jan 18 07:02 PM
Myszkowski Kenneth AllenChief Financial OfficerJan 17Sale14.5581,8751,191,281305,607Jan 18 07:00 PM
GIVEN BRUCE DChief Operating OfficerJan 14Option Exercise2.9012,66636,7651,111,022Jan 16 08:18 PM
Li ZhenSnr. VP, Chem and Non-Clin DevJan 14Sale14.3440,500580,770201,700Jan 16 08:24 PM
GIVEN BRUCE DChief Operating OfficerJan 14Sale14.4042,666614,3901,068,356Jan 16 08:18 PM
Waddill William D.DirectorJan 11Sale14.778,500125,54546,500Jan 11 06:15 PM
Myszkowski Kenneth AllenChief Financial OfficerJan 02Sale11.988,33399,829387,482Jan 03 07:55 PM
GIVEN BRUCE DChief Operating OfficerJan 02Sale11.9820,000239,6001,098,356Jan 03 07:53 PM
GIVEN DOUGLAS BDirectorDec 27Sale12.003,00036,000145,130Dec 28 05:20 PM
Anzalone Christopher RichardChief Executive OfficerDec 19Sale13.9290,0001,252,8001,542,455Dec 21 05:15 PM
Anzalone Christopher RichardChief Executive OfficerDec 12Sale14.0790,0001,266,3001,632,455Dec 14 05:18 PM
GIVEN DOUGLAS BDirectorNov 23Sale12.743,00038,220148,130Nov 26 09:09 PM
Anzalone Christopher RichardChief Executive OfficerNov 09Sale14.3981,5001,172,7051,722,455Nov 09 07:01 PM
Leone Peter BrianVP, Strategic Bus. InitiativesOct 19Option Exercise6.20131,137812,512261,137Oct 23 07:59 PM
Leone Peter BrianVP, Strategic Bus. InitiativesOct 19Sale13.49131,1371,769,038130,000Oct 23 07:59 PM